The robust efficacy and clean safety profile de-risk bempikibart's path to registration in alopecia areata. Monitor for FDA feedback and initiation of Phase 3 trial in 1H27, which could drive significant upside for this $190M market cap biotech. The data also supports expansion into other I&I indications.
Drug in focus
QTTB drug pipeline →bempikibart
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.
- Next catalyst
- None dated
What to watchThe July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027, but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $21.38entry
- T+1 · 4mo ago −13.66%α −14.01% · $18.46
- T+5 · 4mo ago −29.61%α −28.82% · $15.05
- T+20 · 3mo ago −26.71%α −29.89% · $15.67
- T+60 · 6w ago −62.07%α −66.06% · $8.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata. The mITT population (n=25) showed a 35.3% mean SALT reduction and 40.0% SALT-20 response, with no Grade 3 or higher adverse events and negligible anti-drug antibodies. The company plans to advance to a registration-directed program and engage the FDA in 1H27, supporting a differentiated biologic profile in a >$5B US market opportunity.
Key Facts
- Part B mITT (n=25): 35.3% mean SALT reduction at Week 36; SALT-20 response 40.0% (10/25)
- ITT (n=33): SALT-20 response 30.3% (10/33)
- No Grade 3 or higher AEs; injection site reactions in 4% of administrations, all mild
- Negligible anti-drug antibodies with no impact on pharmacokinetics
- Plans to initiate registration-directed program in 1H27 after FDA engagement
- US alopecia areata market estimated >$5B by 2037
Financial Impact
No financial data in filing; positive clinical data supports potential for partnership or funding for registrational trials
Risk Factors
- Small sample size (n=25 mITT) limits statistical power; results may not replicate in larger trials
- Company will need additional capital to fund registrational trials; dilution risk
- Competition from JAK inhibitors with established market presence and black box warnings may limit uptake
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-301520 |
| Document: d143274d8k.htm | 0001193125-26-301520 |
| Document: 0001193125-26-301520-index-headers.html | 0001193125-26-301520 |
| Document: 0001193125-26-301520-index.html | 0001193125-26-301520 |
| Document: 0001193125-26-301520.txt | 0001193125-26-301520 |
Track record
23 reports on QTTB
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers